Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes

Diabetes and Metabolism

Volumn 39, Issue 5, 2013, Pages 445-453

  Blanco, M ^a   Hernandez M T ^b   Strauss, K W ^c   Amaya, M ^d  

^a Novartis Pharma   (Spain)

^b AGS Campo de Gibraltar AP   (Spain)

^c BD POB 13 ^*  (Belgium)

^d Hospital de Algeciras   (Spain)

Author keywords

Costs; Injection rotation; Insulin consumption; Insulin injection; Lipodystrophy; Lipohypertrophy

Indexed keywords

GLUCOSE; INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; HYPOGLYCEMIA; INJECTION SITE; INJECTION SITE LIPOHYPERTROPHY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEEDLE; PREVALENCE; PROCEDURES; RISK FACTOR; SPAIN; ULTRASOUND;

CONSOMMATION D'INSULINE; COSTS; COÛTS; INJECTION D'INSULINE; INJECTION ROTATION; INSULIN CONSUMPTION; INSULIN INJECTION; LIPODYSTROPHIE (LH); LIPODYSTROPHY; LIPOHYPERTROPHY; ROTATION D'INJECTION;

ADIPOSE TISSUE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GUIDELINES AS TOPIC; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTROPHY; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PRIMARY HEALTH CARE; RISK FACTORS; SPAIN; YOUNG ADULT;

EID: 84885935507     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.05.006     Document Type: Article

References (31)

1. Frid A., Hirsch L., Gaspar R., Hicks D., Kreugel G., Liersch J., et al. New injection recommendations for patients with diabetes. Diabetes Metab 2010, 36:S3-S18.
2. De Coninck C., Frid A., Gaspar R., Hicks D., Hirsch L., Kreugel G., et al. Results and analysis of the 2008-2009 Insulin Injection Technique Questionnaire survey. J Diabetes 2010 Sep, 2:168-179.
3. Thow J.C., Johnson A.B., Marsden S., Taylor R., Home P.H. Morphology of palpably abnormal injection sites and effects on absorption of isophane (NPH) insulin. Diabetic Med 1990, 7:795-799.
4. Richardson T., Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 2003, 4:661-667.
5. Holstein A., Stege H., Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Expert Opin Drug Saf 2010 Mar, 9:225-231.
6. Vardar B., Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract 2007, 77:231-236.
7. Seyoum B., Abdulkadir J. Systematic inspection of insulin injection sites for local complications related to incorrect injection technique. Trop Doct 1996, 26:159-161.
8. Hauner H., Stockamp B., Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996, 104:106-110.
9. Personal communication: Lourdes Saez-de Ibarra and Ruth Gaspar, Diabetes Nurses and Specialist Educators from La Paz Hospital, Madrid, Spain, 2010.
10. Overland J., Molyneaux L., Tewari S., Fatouros R., Melville P., Foote D., et al. Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system. Diab Obes Metab 2009, 11:460-463.
11. Strauss K., De Gols H., Letondeur C., Matyjaszczyk M., Frid A. The second injection technique event (SITE), May 2000, Barcelona, Spain. Pract Diab Int 2002, 19:17-21.
12. Saez-de Ibarra L., Gallego F. Factors related to lipohypertrophy in insulin-treated diabetic patients; role of educational intervention. Pract Diab Int 1998, 15:9-11.
13. Schuler G., Pelz K., Kerp L. Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications?. Diab Res Clin Pract 1992, 16:209-212.
14. Nielsen B.B., Musaeus L., Gæde P. Attention to injection technique is associated with a lower frequency of lipohypertrophy in insulin treated type 2 diabetic patients. Abstract European Association for the Study of Diabetes 1998.
15. Johansson U., Amsberg S., Hannerz L., Wredling R., Adamson U., Arnqvist H.J., et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care 2005, 28:2025-2027.
16. Young R.J., Hannan W.J., Frier B.M., Steel J.M., Duncan L.J. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care 1984, 7:479-480.
17. Chowdhury T.A., Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. Br Med J 2003, 327:383-384.
18. Johansson U.B. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care 2005, 28:2025-2027.
19. Frid A., Linden B. Computed tomography of injection sites in patients with diabetes mellitus. Injection and absorption of insulin 1992, Thesis, Stockholm.
20. Clinical practice recommendations 2003. Hypoglycaemia and employment/licensure. Diabetes Care 2003, 26(Suppl. 1):141. American Diabetes Association.
21. Standards of Medical Care in Diabetes-2012. Diabetes Care 2012, 35:S11-S63. American Diabetes Association.
22. Ampudia-Blasco F.J. Postprandial hyperglycaemia and glycemic variability: new targets in diabetes management. Av Diabetol 2010, 26:S29-S34.
23. Hirsch I.B., Bode B.W., Childs B.P., Close K.L., Fisher W.A., Gavin J.R., et al. Self-monitoring of blood glucose (SMBG) in insulin- and non-insulin-using adults with diabetes: consensus recommendations for improving SMBG accuracy, utilization, and research. Diabetes Technol Ther 2008, 10:419-439.
24. Strauss K., De Gols H., Hannet I., Partanen T.M., Frid A. A pan-European epidemiologic study of insulin injection technique in patients with diabetes. Pract Diab Int 2002, 19:71-76.
25. Insulin delivery. Diabetes Forecast 2003, 56:59-76. American Diabetes Association Resource Guide 2003.
26. Insulin administration. Diabetes Care 2004, 27:S106-S107. American Diabetes Association Position Statements.
27. De Meijer P.H.E.M., Lutterman J.A., van Lier H.J.J., van't Laar A. The variability of the absorption of subcutaneously injected insulin; effect of injection technique and relation with brittleness. Diabetic Med 1990, 7:499-505.
28. Ahern J., Mazur M.L. Site rotation. Diabetes Forecast 2001, 54:66-68.
29. Bantle J.P., Weber M.S., Rao S.M., Chattopadhyay M.K., Robertson R.P. Rotation of the anatomic regions used for insulin injections day-to-day variability of plasma glucose in type 1 diabetic subjects. JAMA 1990, 263:1802-1806.
30. Davis E.D., Chesnaky P. Site rotation... taking insulin. Diabetes Forecast 1992, 45:54-56.
31. Volkova N.I., Davidenko I. Lypohypertrophy in patients receiving insulin therapy: state of the art. Diabetes Mellitus. Diagn Manag Treat 2011, 2:80-83.